Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 8, 2016 (11 years ago)

BuPROPion Hydrochloride Extended-release Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, packaged in a) 60-count bottles (NDC 59746-317-60) and b) 100-count bottles (NDC 59746-317-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.

Affected NDCs 59746-0317-01 59746-0317-60

Compare with the code on your package — it is the most precise check available.

Drug: Bupropion Category: Mental Health Medication

Recalling firm
Jubilant Cadista Pharmaceuticals, Inc.
NDC code
59746-317-60
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0671-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bupropion recalls

See all

Other recalls by Jubilant Cadista Pharmaceuticals, Inc.

All 2016 recalls
Class II · Moderate risk

Irbesartan Tablets

Failed Dissolution Specifications

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-447-90 D-1294-2022
Class II · Moderate risk

Irbesartan Tablets

Failed dissolution specifications.

Terminated Dissolution failure Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-448-90 D-1293-2022